Unconfigured Ad

Collapse

NovaSeq X and X Plus from Illumina: Latest Sequencing Technologies—Part 1

Collapse
X
Collapse
  •  

  • NovaSeq X and X Plus from Illumina: Latest Sequencing Technologies—Part 1

    In the Fall of 2022 Illumina announced their newest pair of flagship sequencers: the NovaSeq X and the NovaSeq X Plus. Their development was part of Illumina’s pursuit of lowering the cost of sequencing by dropping the price to approximately $200 per genome. The major differences between Illumina’s previous top sequencer (the NovaSeq 6000) and the NovaSeq X and X Plus are that the new devices have more affordable and updated reagents, faster run times, and the ability to process data directly on the instrument. Here we’ll take a look at these features and explain how they differ from previous models.
    Click image for larger version  Name:	NovaSeq X edited2.jpg Views:	0 Size:	119.0 KB ID:	323373
    Image of the NovaSeq X (courtesy of Illumina)


    Read type and length
    Like all Illumina instruments, the NovaSeq X and NovaSeq X Plus are both short read sequencers. The read lengths vary from 2 x 50 bp up to 2 x 150 bp depending on user selection and the choice of the reagent cartridges (options include 100-, 200-, and 300-cycle kits).

    Flow cell/SMRT cell options
    The three flow cells available with the sequencers (1.5B, 10B, and 25B) are named according to the billions (B) of clusters each are capable of producing. Each flow cell contains 8 independent lanes, which can be used to load 8 separate library pools. The flow cells are patterned like the other production-scale sequencers; however, the improved design positions the nanowells closer together to increase cluster densities and final output. The NovaSeq X only has a single position for a flow cell, but dual flow cell runs are available on the NovaSeq X Plus.


    Data output
    The output on the NovaSeq X varies from 165 Gb on a run of 2 x 50 bp with a 1.5B flow cell up to 8 Tb on a 2 x 150 bp run using a 25B flow cell. Since the NovaSeq X Plus has two flow cells, the data output varies from 165 Gb up to 16 Tb with a dual flow cell run. This is a significant increase when compared to the 6 Tb of maximum output from the NovaSeq 6000. The number of reads has also increased per flow cell to 26 billion reads on single-end runs and 52 billion on pair-end runs.


    Analysis options
    The DRAGEN Bio-IT platform is directly built into the sequencers for faster and simpler data analysis. Users now have the ability to analyze their results on the NovaSeq or the option to process the data in the cloud. In addition, genomic data compression is available using DRAGEN ORA (original read archive) in an effort to reduce the time it takes for data transfer and to alleviate storage constraints. The storage footprint can be reduced up to five times while still preserving all the data.

    Common applications
    ● Whole genome sequencing
    ● Whole exome sequencing
    ● Whole transcriptome sequencing

    Release date
    Both instruments won’t be available for shipment until the first quarter of 2023 and some flow cell options won’t be released until later in the year.

    Highlights
    ● An updated chemistry, XLEAP-SBS, with new dyes, linkers, blockers, and a new polymerase to allow for faster incorporation times and an increased stability of reagents.
    ● Higher data output of up to 16 Tb and a significant reduction in cost per Gb and per read.
    ● An updated 8-lane flow cell that can support 8 separate library pools compared to the 4 lanes with the NovaSeq 6000.
    ● Easy and quicker analysis with onboard analysis tools (DRAGEN Bio-IT) and compressed data.
    ● A more sustainable system with compacted cartridges and lyophilized consumables that don’t need dry ice for shipment.

    To compare sequencing technologies please visit Biocompare
      Please sign into your account to post comments.

    About the Author

    Collapse

    seqadmin Benjamin Atha holds a B.A. in biology from Hood College and an M.S. in biological sciences from Towson University. With over 9 years of hands-on laboratory experience, he's well-versed in next-generation sequencing systems. Ben is currently the editor for SEQanswers. Find out more about seqadmin

    Latest Articles

    Collapse

    • Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
      by SEQadmin2



      Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

      Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
      ...
      10-14-2026, 09:55 AM
    • New Genomics Technologies Take Aim at Long-Standing Limits
      by SEQadmin2


      Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

      We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
      ...
      09-28-2026, 10:25 AM
    • How Immunogenomics Decodes Immunity’s Genetic Blueprint
      by SEQadmin2




      The immune system’s power comes from its genetic diversity, allowing myriad threats to be neutralized through first recognizing foreign antigens. That diversity is also what makes the immune system so difficult to study. Recent advances in sequencing technology and computational biology, however, are giving researchers new tools to understand immune responses and immune-related diseases in greater detail.

      This convergence of genetics, immunology, and computation...
      09-01-2026, 05:41 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Working...